ERBB2 and salivary gland cancer: The salivary gland cancer cohort from the phase II MyPathway basket trial showed that combined trastuzumab and pertuzumab has an ORR of 60%, with a DOR of 9.2 months, PFS of 8.6 months and OS of 20.4 months in previously treated patients (1–3 prior lines) with advanced HER2-positive salivary gland tumors [83].